May 24, 2017 12:00 PM EDT
Pharma

Puma wins a big round in fight for ner­a­tinib OK as ex­perts of­fer a cru­cial thumbs up

John Carroll

Editor & Founder

Puma Biotech­nol­o­gy $PBYI won a cru­cial vote in fa­vor of its ex­per­i­men­tal breast can­cer drug ner­a­tinib, with a ma­jor­i­ty of out­side ex­perts of­fer­ing the FDA …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Out­look's shares crash as wet AMD drug flunks Phase 3 test

A service from the Financial Times